Supernus Pharmaceuticals, Inc.
Treatment Of Central Nervous System, Drug Development, Tablets, Capsules, Research & Development
Treatment Of Central Nervous System, Drug Development, Tablets, Capsules, Research & Development
Supernus is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. They market two products, Oxtellar XR and Trokendi XR in the U.S. Oxtellar XR and Trokendi XR are the first once-daily extended release oxcarbazepine and topiramate products indicated for the treatment of epilepsy in the U.S. market.
We have 425 contacts in our database, out of which 17% are decision makers. The distribution of leads are as follows:
In October, 2019 supernus.com's total website visitor was 5213, increased by 181% from previous month. Some key metrics are Average time spent on site is 3 minutes, Bounce Rate is 38% and average page per visit is 4 respectively.
We Verified supernus.com server for email deliverability.
Microsoft today declared that it has acquired Affirmed Networks, an organization that specializes...
Perficient acquires Catalyst Networks, a Georgia corporation doing business as Brainjocks, which ...
Cognizant enters into an agreement to acquire the U.S.-based digital marketing consultancy Lev fo...
Masimo has agreed to acquire Germany-based TNI Medical AG for an undisclosed sum.
© Copyright 2014-2020 by GetCompanyInfo.com. All Rights Reserved.
